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a Scottish doctor, William Hunter, documented that chondral 
lesions had been considered diffi   cult to treat and heal from the 
time of Hippocrates. In cases where chondral defects involve the 
subchondral bone causing bleeding, mesenchymal stem cells 
or fi  broblasts promote repair with fi  brocartilage. Unfortunately, 
fibrocartilage is biomechanically inferior to hyaline cartilage 
and eventually results in osteoarthritis
1,2). Therefore, the goal 
of treatment for articular cartilage defects is to regenerate 
hyaline-like cartilage to prevent osteoarthritis
3). Total knee 
replacement can be helpful for patients with advanced age and 
severe osteoarthritis, but there are only a few options for young 
osteoarthritic patients. For successful focal chondral defect 
treatment, the prevalence of articular cartilage damage, structures 
and characteristics of the articular cartilage, post-injury 
responses, and scientifi  c bases and clinical outcomes of various 
treatment methods should be well understood.
Treatments
  Th   e goal of focal chondral defect treatment is to enable patients 
to return to normal activities or active lifestyle through pain relief 
and joint function improvement. Th   e treatment decision should 
be based on the patient’s activity level, age, cause, size and depth 
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degenerative arthritis.
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Introduction
  Articular cartilage is devoid of vascular, nervous and lymphatic 
tissue and chondrocytes are unable to participate in the healing 
or repair process of damaged tissue because of extracellular 
matrix that surrounds the cartilage cells. About 200 years ago, 
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of defects, and presence of combined defects. Available treatment 
options include conservative treatment, surgical treatment for 
symptom relief or articular cartilage restoration. 
1. Conservative Treatment
  Conservative treatment for chondral defects of the knee can 
be effective for pain relief, but it cannot be used for articular 
cartilage restoration. Craig et al.
4) suggested that conservative 
treatment can be an option when mild pain is present or the 
risk of surgery is greater than its benefi  t. Messner and Maletius
5) 
followed up 28 patients with isolated chondral damage of the 
knee for 14 years and concluded that conservative treatment 
was not helpful in preventing the progress of the damage: the 
patients had excellent or good clinical results, but radiographic 
examination revealed abnormal fi  ndings in ≥50% of the patients. 
Conservative treatment includes the use of non steroid anti 
infl  ammatory drugs (NSAIDs), pain killers, hormones (estrogen 
and growth hormone), chondroprotective agents (glucosamine & 
chondroitin phosphate and omega-3), intraarticular injections of 
steroids or hyaluronic acid, weight loss to reduce the load on the 
knee joint, braces, and physical treatment. Unfortunately, these 
methods can be useful for symptom relief only not for restoring 
structural integrity of the articular cartilage
6). 
2. Surgical Treatment 
  The purpose of surgical treatment is to improve symptoms 
and prevent degenerative changes by achieving structural and 
biomechanical restoration of the articular cartilage. Surgical 
treatment methods can be broadly divided into arthroscopic 
lavage and debridement, cell-based therapy (subchondral 
bone stimulation for chondral tissue differentiation or culture 
and implantation of chondrocytes), and tissue-based therapy 
(osteochondral autograft transplantation or osteochondral 
allograft   transplantation). Th   e advantages/disadvantages of each 
method, size, location, and depth of a lesion, and the patient’s age 
and activity level should be assessed to determine an appropriate 
treatment method. However, the two most important factors that 
should be considered are the cause and characteristics of chondral 
defects. Chondral lesions can be either focal or degenerative. For 
the treatment of focal lesions, suffi   cient debridement should be 
performed to maintain the adjacent area in the articular cartilage 
healthy for successful structural and biomechanical restoration. 
In contrast, for degenerative lesions where the defective and 
transitional area is wide, a sufficient debridement may restrict 
subsequent treatment options or cause unfavorable results. In 
addition, poor cell/tissue regeneration ability may result in less 
than satisfactory outcome after surgery. Therefore, the cause 
and characteristics of chondral lesions should be taken into 
consideration in performing surgical treatment. 
1) Arthroscopic lavage and debridement
  There has been a transition from open to arthroscopic lavage 
and debridement of chondral lesions. Arthroscopic lavage is to 
remove infl  ammatory mediators that may be responsible for joint 
eff  usion and loose cartilage and collagen debris. Debridement of 
articular cartilage (chondroplasty) is a procedure for removing 
unstable cartilage fragments or margins of the cartilage that 
may cause joint impingement with a curette or a shaver in order 
to alleviate joint pain and prevent additional articular cartilage 
destruction. Jackson et al.
7) observed clinical improvements in 
80% of their patients at 3.5 years aft  er arthroscopic debridement 
and correlated degenerative changes with clinical outcome. 
However, Kirkley et al.
8) reported that arthroscopic surgery for 
knee cartilage defects provided no additional benefi  t to optimized 
physical or medical therapy. Arthroscopic repair can be helpful 
for preventing the progress of delamination of articular cartilage, 
but there is controversy over its influence on the long-term 
longevity of the articular cartilage.
2) Cell-based therapy
  Cell-based therapy is a promising approach using the patient’s 
own cells for the treatment of chondral defects. There are 
marrow stimulating procedures and autologous chondrocyte 
implantation (ACI). Marrow stimulating procedures include 
abrasion arthroplasty, drilling, and microfracture. However, the 
former two are currently rarely performed because they have 
been associated with poor clinical outcome.
  (1) Microfracture
  Microfracture is an articular cartilage repair technique in 
which tiny fractures are made 2-4 mm apart from each other 
to cause bleeding in the subchondral bone and fibrin clots in 
the perforations release mesenchymal stem cells that would 
diff  erentiate into chondrocytes
9).
  Multi-potential mesenchymal stem cells can differentiate into 
fibrocartilage cells and chondrocytes and induce fibrocartilage 
or hyaline-like cartilage formation. Fibrocartilage contains 
more collagen and less proteoglycans compared to hyaline 
cartilage. It is composed of more type I collagen than type 
II collagen. Type I collagen has lower compressive strength, 
elasticity, and wear resistance compared to type II collagen. 
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under repeated mechanical stress. In addition, the number of 
mesenchymal stem cells is small and tends to decrease over 
time
10). In spite of these disadvantages, microfracture has become 
a preferred procedure because it does not cause damage to other 
normal regions and is easy to perform and relatively economical.
  Microfracture can be used for unstable or full-thickness (Outer-
bridge grade 3 or 4) focal chondral defects or degenerative arthritis 
with good knee alignment. Th   e procedure is contraindicated for 
patients with infl  ammatory arthritis, lower limb malalignment, 
partial-thickness (Outerbridge grade 1 or 2) chondral defects, 
or reluctance to participate in rehabilitation. There are other 
considerations that should be taken into account. Th   e older the 
patient is, the poorer the treatment outcome. Traumatic lesions 
have been associated with better treatment results compared 
to degenerative lesions. Theoretically, microfracture can be 
performed regardless of the size of a lesion. However, Steadman 
et al.
11) described that lesions larger than 400 mm
2 responded 
worse to the treatment. In addition, the higher the body mass 
index, the poorer the treatment outcome. Th   e procedure consists 
of debridement and drilling. Debridement should be performed 
thoroughly. All loose cartilage should be completely removed 
to make the lesion surrounded by healthy cartilage and form 
perpendicular edges to create a well shouldered lesion (Fig. 1). 
Th   is is intended to make marrow clots fi  rmly adhere to the lesion 
and reduce direct load across the lesion for stable recovery. Th  e 
remaining calcifi  ed cartilage layer should be completely removed 
because it inhibits attachment of repair tissue
12). During this 
procedure, care should be taken to avoid excessive damage to 
the subchondral bone. Subchondral bone drilling should be 
performed in a centripetal manner from the margin to the center 
of the lesion. Microfracture holes should be placed 3-4 mm apart 
from each other and 4-5 mm in depth (Fig. 1)
13). An appropriate 
depth can be determined by observing fat droplets that is 
released from the marrow through the microfracture holes while 
controlling the perfusion pressure (Fig. 1). 
  Different postoperative rehabilitation regimens are adopted 
according to the location of a lesion. For femorotibial joint 
lesions, continuous passive motion exercise is initiated immedi-
ately after surgery. Steadman et al.
14) reported that full passive 
range of motion could be obtained aft  er 6 to 8 weeks of toe touch 
weight bearing and continuous passive motion exercise that 
had been started immediately after surgery. For femoropatellar 
joint lesions, care should be taken not to apply shear force on 
the lesions using a brace that allows for 0-20 degrees of joint 
movement. On the other hand, Marder et al.
15) suggested that 
postoperative physical treatment or weight bearing does not 
Fig. 1. Surgical procedure of microfracture. (A) Unstable cartilage fl  ap and calcifi  ed cartilage bed is debrided with open curette. (B) It is important 
to debride the calcifi  ed cartilage layer and make a well-contained pocket surrounded healthy cartilage (well-shouldered). (C) Subchondral bone is 
punctured with an awl. (D) Microfracture is circumferentially performed from periphery to center. (E) Th   e penetration of subchondral bone is 3 
to 4 mm deep and apart. (F) Arthroscopic photograph showing the fi  nal step of microfracture. (G) Mesenchymal blood egress from bone marrow 
through subchondral holes. (H) It is important for tissue regeneration to keep the mesenchymal clot in the defect.188    Seo et al. Management of Focal Chondral Lesion in the Knee Joint
have to be avoided when lesions are “well shouldered” during 
operation because the repair tissue is not affected by weigh 
bearing based on their observation that aggressive physical 
treatment did not infl  uence the treatment outcome. 
  In summary, various studies have shown that microfracture can 
be helpful in improving overall symptoms of chondral defects, 
but the symptoms worsen over time and poor clinical outcome 
can be attributed to advanced age, large lesion size, and high 
activity level
16-19).
  (2) Autologous chondrocyte implantation 
  ACI is a two-stage procedure in which chondrocytes harvested 
from a non-weight bearing portion of the articular cartilage are 
implanted into a defect. Compared to other treatment methods 
for chondral defects, ACI causes less damage to the subchondral 
bone plate and trabecula, can be performed on larger lesions, 
does not cause donor-site discomfort or complications, and is 
relatively easy to perform. However, the procedure requires joint 
excision, should be done in two separate steps, and involves a 
long rehabilitation period
20). 
  The best candidates for ACI are patients who are between 15 
and 55 years of age with full-thickness (Outerbridge stage 3 or 
4) focal chondral defects or unstable osteochondritis dissecans. 
Procedures for lower limb malalignment or ligament instability 
can precede ACI if necessary. The ideal lesion size for the pro-
cedure is 2 to 10 cm
2. In case of osteochondral lesions, ACI can 
be performed for lesions that are 6-8 mm in depth and bone 
grafting should precede ACI for deeper lesions. Although ACI 
can be performed regardless of the location of a lesion in the 
knee, best clinical results can be expected for lesions in the 
femoral condyle. ACI is contraindicated for patients who are 
not cooperative with postoperative rehabilitation or who have 
infl  ammatory arthritis or a kissing lesion (Outerbridge stage 3 or 
4 lesion on the opposing articular surface). 
  The first stage of ACI involves an arthroscopic inspection of 
the focal lesion to assess the size, depth, and potential bone 
loss. Lesions 6 to 8 mm deeper than the subchondral bone may 
require bone graft  ing prior to ACI. Th   e opposing surface of the 
cartilage defect should also be examined. An Outerbridge stage 
1 or 2 lesion on the opposing surface can be considered a relative 
contraindication to ACI. Next, chondrocytes should be harvested 
using gouges or curettes from a low weight bearing area of the 
knee including the lateral margin of the intercondylar notch 
or the superomedial trochlea of the femur. The approximate 
size of the biopsy should be 200-300 mg. The subchondral 
bone should be penetrated to allow a fibrocartilage repair of 
the donor site. Th   e second stage of the procedure is performed 
4 weeks after the biopsy when sufficient cells are cultured. The 
surgical site depends on defect location with use of a medial or 
lateral parapatellar mini-arthrotomy. All unstable or damaged 
cartilage is removed to make the lesion surrounded by stable 
and healthy cartilage that forms vertical walls to create a well-
shouldered lesion. The neighboring cartilage should be 2 to 
3 mm thick to accommodate suture fixation of the periosteal 
graft  . Th   e lesion should be debrided to be in a circular or an oval 
shape to facilitate tight suturing of the graft  . Th  e  calcifi  ed layer 
in the bed of the lesion is removed and the subchondral bone is 
exposed. During this procedure, care should be taken to avoid 
subchondral bone damage that would cause bleeding from bone 
marrow and contamination of the transplanted chondrocytes 
with undifferentiated cells. Subsequently, a periosteal flap that 
will cover the cartilage defect should be harvested from the 
proximal medial tibia or a site distal to the pes anserine insertion. 
Th  e  fi  brous tissue and fat of the periosteum should be removed. 
Using a template made of aluminum foil or paper, the size of the 
defect is measured. Th   e periosteal fl  ap should be larger than the 
lesion by 1 to 2 mm and care should be taken not to penetrate it. 
Th  e  fl  ap is sutured to the cartilage with the cambium layer facing 
the defect using a 6-0 absorbable suture. Closely spaced sutures 
should be performed leaving an opening in the most superior 
portion of the lesion for the injection of chondrocytes with an 
18-guage angiocatheter. The injection should be performed 
carefully from the bottom upwards to ensure even distribution 
of the chondrocytes throughout the lesion. Th   e opening is closed 
with suture and sealed with fi  brin glue (Fig. 2).
  Rehabilitation after ACI is a long and challenging process 
because it is a cell-based therapy as microfracture. Rehabilitation 
protocols vary according to the location of a lesion and condition 
of the surgical site. Weight-bearing or movement of the knee is 
restricted for 12 to 18 hours aft  er surgery until the chondrocytes 
are embedded within the articular cartilage. Joint exercise using 
a continuous passive motion (CPM) machine is performed 6 
to 8 hours per day for the first four postoperative weeks. For 
the first two postoperative weeks, weight-bearing is avoided. 
Between the second and fourth postoperative week, 10-20 kg 
of weight bearing is allowed and between the fourth and sixth 
postoperative week, walking with the aid of a crutch is allowed. 
Weight-bearing is progressed over the 12 postoperative weeks 
to full weight bearing. Until the second postoperative week, the 
knee should be immobilized in a brace in full extension except 
when a CPM or joint exercise is performed. Th   e range of motion 
should be increased gradually with use of a CPM machine
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  Peterson et al.
22) observed good to excellent results in 50 out of 
61 patients at two years after ACI and in 51 out of 60 patients 
at eleven years aft  er ACI. A second-look arthroscopy showed a 
normal appearance of the cartilage in 90% of the 8 patients and 
hyaline cartilage was confirmed by histological examination in 
most of the patients. Factors that could influence the outcome 
of ACI have also been addressed in many studies. Minas et 
al.
23) reported that prior procedures using marrow stimulating 
techniques such as microfracture increase the failure rates of 
ACI. Mithoefer et al.
24) observed poor clinical results in patients 
with large or multiple cartilage lesions. Saris et al.
25) documented 
that the longer the duration of symptoms before ACI was, the 
poorer the clinical results. Knutsen et al.
26) noted that patients 
under 30 years of age with high activity had good clinical results 
after ACI. These studies indicate that various factors should be 
taken into consideration to achieve satisfactory outcome aft  er the 
procedure.
  The first generation ACI has often been associated with 
periosteal complications. Kreuz et al.
27) reported that clinical 
improvement was observed in most of the patients after ACI, 
but MRIs revealed periosteal hypertrophy in 28% of the total 
patients and in 50% of the patients with ACI for chondral defects 
in the knee. Seo et al.
28) reported that ACI for chondral defects 
of the femoral condyle resulted in clinical improvement, but 
the International Cartilage Repair Society (ICRS) assessment 
revealed abnormal fi  ndings in 60% and graft   hypertrophy in 21% 
of the patients (Figs. 3, 4). 
  The first generation ACI has been replaced by the second 
and then the third generation ACI to prevent periosteal 
complications and obtain structurally and biomechanically 
superior tissue. The second generation ACI is a procedure in 
which a synthetic collagen membrane instead of a periosteal 
fl  ap is sutured to the defect and chondrocytes are injected. Th  e 
third generation ACI is a procedure in which chondrocytes are 
cultured in a biodegradable scaffold that will be implanted in 
the defect. Although various studies have addressed the results 
Fig. 2. Surgical procedure of the 1st generation autologous chondrocyte implantation. (A) Outerbridge 4 lesion in the medial femoral condyle. (B) 
Debridement of the calcifi  ed cartilage layer and unstable chondral fl  ap. (C) Defect size is measured with a sterile paper. A 2 mm oversized template 
is needed. (D) Periosteal flap is excised from the proximal medial tibia. (E) The periosteal flap watertightly covers the defect. (F) Chondrocyte 
suspension is injected to the defect through a plastic 18-gauge angiocath needle.190    Seo et al. Management of Focal Chondral Lesion in the Knee Joint
of each procedure, more studies should follow to confi  rm those 
results
29-35).
  ACI is useful for maintaining good clinical outcome for a 
long-term period in cases of focal cartilage defects, but the 
disadvantages include that it requires two separate procedures 
for chondrocyte collection and implantation and joint excision is 
unavoidable in most cases during implantation. With the advent 
of the second and third generation ACI technique, the procedure 
can be performed arthroscopically and has become easier to 
perform. We expect further improvements will be made in the 
future. 
3) Tissue-based therapy
  Tissue-based therapy includes osteochondral autograft trans-
plantation, osteocondral allograft transplantation, and tissue 
engineered scaffold implantation. The advantages of these 
procedures are treating defects in one stage, promoting 
rapid return to daily living activities and sports with use of 
biomechanically healthy tissue, and maintaining postoperative 
results for a long-term period due to hyaline cartilage repair. 
Since tissue engineered scaffold implantation can be used in 
limited clinical settings and accordingly only a small number of 
clinical results have been reported, we describe the former two 
methods in this review article.
Fig. 3. MRI fi  ndings before and aft  er auto-
logous chondrocyte implantation (ACI). (A) 
Coronal proton density image showing the 
focal chondral defect with thinning of the 
cartilage. (B) Coronal proton density image 
showing the slightly hyperintense repaired 
tissue at 26 months after ACI. (C) Sagittal 
T2 fast spin echo (FSE) image showing 
the thinning of the cartilage and irregular 
elevation of the subchondral bone plate. 
(D) Sagittal T2 FSE image showing the 
hypertrophied regenerated cartilage tissue 
with focal hyperintense area at 26 months 
aft  er ACI.
Fig. 4. Second look arthroscopic findings 
aft  er autologous chondrocyte implantation 
(ACI). (A) Regenerated hyaline like tissue 
aft  er ACI, of which surface shows a smooth 
and well-incorporated margin. (B) Graft 
hypertrophy after 1st generation ACI, 
which causes a locking of the knee.Knee Surg Relat Res, Vol. 23, No. 4, Dec. 2011    191
  (1) Osteochondral autograft   transplantation (OAT, mosaicpla-
sty)
  OAT can be a solution for hyaline repair of chondral defects. 
The advantages of this technique include: 1) it is a one-stage 
procedure unlike ACI; 2) it can be performed arthroscopically 
for small lesions; 3) osteochondral plugs can be obtained with 
ease; 4) it is a tissue-based therapy that allow earlier rehabilitation 
compared to cell-based therapy; 5) it can be performed at a 
lower cost compared to ACI; 6) the lesion is covered by hyaline 
cartilage; and 7) it results in few complications. One of the 
disadvantages of the procedure is that it cannot be applied for 
large lesions due to limited donor site availability. For large 
lesions, multiple osteochondral plugs are necessary, but it is 
diffi   cult to coordinate the height and direction of the implanted 
osteochondral plugs with the adjacent native cartilage. Th  e  gaps 
between osteochondral plugs and between the plugs and the 
surrounding cartilage are filled with fibrocartilage. In addition, 
posttraumatic arthritis may develop in the patellofemoral joint 
due to graft   harvest.
  The primary indication for OAT
36) is a symptomatic anterior 
cartilage defect (Outerbridge stage 3 or 4) that is 1.0-4.0 cm
2 in 
size in patients less than 45 years of age. The contraindications 
include patients above 50 years of age, larger than 8.0 cm
2 lesions, 
moderate or severe osteoarthritis, infl  ammatory arthritis, lack of 
appropriate donor site, and noncompliance with rehabilitation. 
Besides, lower limb alignment and combined ligament injuries 
should also be assessed and treated prior to OAT.
  Th   e procedure consists of defect preparation, graft   harvesting 
with a tubular chisel and graft removal from the chisel, and 
transplantation of the graft
36). On defect preparation, unstable 
cartilage is removed and the size of a lesion is measured to 
determine the size, number, and arrangement of osteochondral 
plugs. Th   e most common donor sites are the superolateral aspect 
of the femoral intercondylar notch and the medial/lateral margin 
of the femoral trochlea. Th   e osteochondral plug can be harvested 
using a tubular chisel and the appropriate length is 15 mm
37). 
It is important to direct the tubular chisel perpendicular to the 
articular surface to obtain a graft   that has a level articular surface. 
Th  e  graft   is ejected from the chisel by tapping the osseous tissue, 
not the articular surface. Next is the transplantation of the 
osteochondral plug into the defect, which consists of drilling, 
dilation, and delivery. An appropriately sized drill guide is placed 
perpendicular to the walls of the lesion and the same diameter 
drill bit is introduced to create a tunnel in the lesion. Th  e  tunnel 
Fig. 5. Surgical procedure of osteochondral autograft   transplantation. (A) Arthroscopic determination of the number and size of graft  s needed aft  er 
debridement of cartilage lesion. (B) Open procedure. (C) Harvesting the osteochondral plug with a tubular chisel from the lateral supracondylar 
ridge. Th   e tubular chisel must be perpendicularly located to the chondral surface. (D) Introduction of the osteochondral plug through a drill guide. 
(E) Harvested osteochondral plugs. Size and length of plugs are marked on the wet gauze. (F) Focal cartilage defect reconstructed with multiple 
osteochondral plugs. It is important to make a congruent surface with the adjacent cartilage.192    Seo et al. Management of Focal Chondral Lesion in the Knee Joint
should be approximately 2 mm longer than the graft   length and 
widened with a dilator of the same diameter. Th  e  graft   is gently 
tapped into the hole using a delivery tamp to avoid chondrocyte 
death
38). When several graft  s need to be implanted, the procedure 
is repeated for each graft to increase mechanical stability. It is 
crucial to ensure that the articular surface of the graft is level 
with the adjacent articular surface (Fig. 5). In a biomechanical 
study conducted by Koh et al.
39), when a graft   was placed slightly 
deeper than the adjacent articular cartilage, the contact pressure 
was normal, whereas 2 mm elevation of a graft resulted in an 
approximately 50% increase in the pressure
39). In an animal 
study, cartilage necrosis and fibrous overgrowth were observed 
when graft  s were placed 2 mm deeper than the adjacent articular 
cartilage
40).
  OAT allows rapid rehabilitaiton
36). Continuous passive motion 
and straight leg raising are performed immediately aft  er surgery. 
Weight bearing is allowed depending upon the number of the 
implanted grafts. Generally, non-weight bearing or tip-toe 
walking with use of a crutch is permitted for 2 postoperative 
weeks. Partial weight bearing is allowed for two or four 
postoperative weeks and full weight bearing is possible from the 
fourth or sixth postoperative week.
  The clinical outcome of OAT is relatively favorable. Many 
studies have shown that the technique was eff  ective in 76-93% of 
the patients in achieving clinical improvement. However, there 
are some factors that could infl  uence the clinical outcome. Jacob 
et al.
41) noted high complication/reoperation rates in patients 
with large-sized lesions. Seo et al.
42) reported that although OAT 
resulted in good clinical outcome, the improvement was relatively 
less remarkable in patients who were ≥30 years of age or had ≥4.0 
cm
2 lesions (Fig. 6).
  (2) Osteochondral allograft   transplantation
  Osteochondral allograft transplantation can be performed 
regardless of the size of a lesion and donor site availability and 
morbidity. The procedure can be employed for treating large 
lesions, ≥10 cm
2 in size
43). The drawbacks of the procedure 
include the difficulty of obtaining grafts in a timely manner, 
Fig. 6. Osteochondral plug fi  xation for the treatment of osteochondritis dissecans (OCD). (A) Sagittal T2 fast spin echo (FSE) image showing stage 
3 OCD lesion in the medial femoral condyle. Th   e lesion is partially separated. (B) Coronal T2 fat suppression FSE image showing OCD lesion with 
focal bone marrow edema. (C) Fixation of OCD with multiple osteochondral plugs. (D) Sagittal image. (E) Coronal image showing the OCD lesions 
completely incorporated to the host bone at 24 months aft  er surgery.Knee Surg Relat Res, Vol. 23, No. 4, Dec. 2011    193
high cost, and the possibility of immune rejection response and 
disease transmission
44). According to the graft type, there are 
shell type and deep type allografts. Shell type grafts include <1 
cm subchondral bone and deep type grafts include the deeper 
layer of subchondral bone. According to the graft preservation 
method, there are fresh allografts, cryopreserved frozen 
allograft  s, and fresh frozen allograft  s. Fresh allograft  s are stored 
at 4
oC and implanted within 1 week of harvesting. Compared 
to other grafts, fresh allografts have relatively high risk of 
immune rejection response or disease transmission because it 
is diffi   cult to completely remove donors’ blood from the graft  s. 
Cryopreservation is a process where allografts are preserved in 
glycerol or dimethyl sulfoxide to minimize chondrocyte death 
and maintain chondrocyte viability. It is effective for long-
term tissue preservation and prevention of immune rejection 
response and disease transmission, but it has been associated 
with low survival rates of chondrocytes. Regarding the fresh 
frozen preservation, graft  s are frozen at -80
oC immediately aft  er 
harvesting and accordingly carry low risk of infection or immune 
response. This procedure costs less than Cryopreservation 
does. However, chondrocytes are destroyed during freezing and 
biomechanical properties of extracellular matrix deteriorate over 
time
45,46).
  Th   e ideal indications for osteochondral allograft   transplantation 
include traumatic osteoarthritis combined with extensive 
cartilage defects or subchondral bone defects in active patients, 
osteochondritis dissecans, and focal avascular necrosis. The 
contraindications include moderate or severe degenerative 
arthritis, inflammatory arthritis such as degenerative arthritis, 
and steroid-induced osteonecrosis
47).
  Gross et al.
48) reported long-term follow-up results of the 
use of fresh osteochondral allografts for post-traumatic knee 
defects: the survival rate was 95%, 80%, and 65% at 5, 10, and 
15 years aft  er surgery, respectively. According to Ghazavi et al.
49) 
osteochondral allograft transplantation resulted in successful 
outcome in 85% and failure in 15% of the cases at 7.5 years aft  er 
surgery. Regarding the factors that infl  uence the osteochondral 
allograft transplantation, Ghazavi et al.
49) attributed failure to 
bipolar tibial and femoral defects, malaligned knees, and workers’ 
compensation status. Osteochondral allograft transplantation 
can be advantageous in maintaining satisfying results for isolated 
extensive chondral or ostechondral defects that cannot be 
managed with OAT or ACI. 
Conclusions
  Chondral defects are difficult to treat. Various recent studies 
have introduced new repair techniques and reported clinical 
results. However, there is no consensus regarding which 
method is superior to the others. Factors that should be taken 
into consideration in determining a surgical method for focal 
chondral defects include the cause of the defect, concomitant 
defects, the patient’s age and activity level, knee alignment, defect 
size, cost, and risk of surgery. Degenerative defects cannot be 
properly managed with surgical repair of articular cartilage. For 
patients with low activity, arthroscopic debridement is the only 
Fig. 7. Treatment algorithm for focal chon-
dral lesions. Before treatment, it is important 
to assess the presence of correctable lesions 
(alignment, stability etc.). The treatment 
decision is guided by the size of the defect 
and the patient’s demands. OB: outerbridge, 
MF: microfracture, OAT: osteochondral 
autograft transplantation, ACI: autologous 
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option for knee defects irrespective of the size. Concomitant 
defects on the aff  ected knee or malalignment should be treated 
before surgical articular cartilage repair. For lesions that are 1-2 
cm
2 in size, microfracture or arthroscopic debridement can be 
a treatment of choice in patients with low activity whereas OAT 
is eff  ective in patients with high activity. ACI can be a solution 
when patients with high activity lack sufficient donor sites or 
microfracture or OAT resulted in failure. For lesions larger than 4 
cm
2 in size, ACI is the most preferred method and bone graft  ing 
should be additionally performed when bone loss is present. 
Osteochondral defects larger than 10 cm
2, focal osteonecrosis, 
and post-traumatic osteochondral defects are treated with 
osteochondral allograft   transplantation (Fig. 7). 
  Articular cartilage does not respond well to healing. Damage 
to the articular cartilage eventually degenerates into arthritis. 
Th   e goal of current techniques for chondral defects is to prevent 
the degenerative process by regenerating hyaline like cartilage. 
Among various methods that have been introduced to achieve 
this goal, the optimal treatment choice should be based on the 
understanding of the theoretical backgrounds, indications, 
surgical technique, rehabilitation, complications, and clinical 
course of the treatment.
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